Building on our inheritance: Genomic technology in healthcare

A report by the Human Genomics Strategy Group.

A new report on genomic technology highlights the UK’s achievements in genetics research to date and makes recommendations to government to ensure future benefit of genomic innovation for the NHS and patients.

Click [here](#) for the full report.

You can also find an interesting [comment](#) on BioNews by EuroGentest member Dr Stuart Hogarth and Prof Paul Martin.

The Brocher Foundation

The Brocher Foundation offers to researchers the opportunity to organize a one and a half day interdisciplinary symposium or a two, three or four day interdisciplinary workshop on the ethical legal and social implications on humankind of recent medical research and new medical technologies.

These symposia and workshops are an occasion to take advantage of a uniquely located Conference room on the shores of Lake Geneva and to invite experts from the numerous international organizations and non governmental organizations based in the area (WHO, UNAIDS, WIPO, WTO, ILO, WMA, ICRC, MSF, etc).

We encourage EuroGentest2 participants to take a closer look at this opportunity to include their dissemination activities!

The deadline for submission is 8 April 2012!

For more information about this call for proposals please visit the Brocher Foundation website [www.brocher.ch](http://www.brocher.ch) or contact our staff at scientificprog@brocher.ch.

Report of the expert meeting on Preimplantation genetic diagnosis (PGD) and gamete testing

The objectives of this first meeting were to edit some guidelines for PGD for Cystic Fibrosis (CF) in order to define the basis for an international harmonization of technological protocols. This meeting, organised by work package 10 of EUGT2 was held in Montpellier (France) on December 14th 2011.

Several experts in PGD for CF from different European countries (UK, Belgium, Greece, Spain, and Italy) as well as one expert from the USA attended the meeting.

In the morning, each participant presented his activity, the techniques used and results obtained. In the afternoon, a round table was organized to discuss different points: nomenclature, strategies to use, markers used, inclusion/ exclusion criteria (according to the severity of CF mutations) and reporting.

A draft of the guidelines has been written and should be finalized before summer 2012. The next meeting will be organized in Montpellier in June 2012 and will be dedicated to PGD guidelines for triplet disorders.

Publications

- **Definitions of genetic testing in European legal documents**
  The purpose of this work was the collection and analysis of European (and other) legislation and policy instruments regarding genetic testing, to scrutinise the definitions of genetic testing.

- **Genetic testing legislation in Western Europe—a fluctuating regulatory target**
  An interesting review article that examines the legal framework governing the use of genetic tests in the clinical setting in Western Europe.

- **The role of disease characteristics in the ethical debate on personal genome testing**
  In this paper, the authors identify and discuss four disease characteristics - severity, actionability, age of onset, and the somatic/psychiatric nature of disease - and show how these lead to specific ethical issues.
Other

- Connect to EuroGentest on LinkedIn
- In the participant section of the EuroGentest website, some interesting general documents from the EC website are highlighted
- Read more about EuroGentest

www.eurogentest.org - Tel: +32 16 34 0321 - Fax: +32 16 6060 - webmaster@eurogentest.org